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Key messages
What is already known about this subject?
 ► The interferon signature is an imporant 
biomarker for disease activity and vascular 
disease in systemic lupus erythematosus and 
antiphospholipid syndrome.
 ► The interferon signature is assessed by 
gene-expression analysis which hampers its 
implication in clinical practice.
What does this study add?
 ► Galectin-9 correlates with disease activity and is 
a robust and easy to measure serum biomarker 
to detect the interferon signature in systemic 
lupus erythematosus and antiphospholipid 
syndrome.
 ► Galectin-9 outperforms CXCL-10 or traditional 
markers of disease activity to detect the 
interferon signature in systemic lupus 
erythematosus and antiphospholipid syndrome.
How might this impact on clinical practice or 
futue developments?
 ► Serum levels of galectin-9 may aid clinical 
decision making in steering anti-interferon 
targeted therapies in patients with systemic 
lupus erythematosus and antiphospholipid 
syndrome.
ABsTrACT
Objective the interferon (iFn) signature is related to 
disease activity and vascular disease in systemic lupus 
erythematosus (sLe) and antiphospholipid syndrome 
(Aps) and represents a promising therapeutic target. 
Quantification of the iFn signature is currently performed 
by gene expression analysis, limiting its current 
applicability in clinical practice. therefore, the objective of 
this study was to establish an easy to measure biomarker 
for the iFn signature.
Methods serum levels of galectin-9, CXCL-10 (ip-10) 
and tumour necrosis factor receptor type ii (tnF-rii) 
were measured in patients with sLe, sLe+Aps and 
primary Aps (pAps) and healthy controls (n=148) after 
an initial screening of serum analytes in a smaller cohort 
(n=43). Analytes were correlated to measures of disease 
activity and the iFn signature. the performance of 
galectin-9, CXCL-10 and tnF-rii as biomarkers to detect 
the iFn signature was assessed by receiver operating 
characteristic curves.
results Galectin-9, CXCL-10 and tnF-rii were elevated 
in patients with sLe, sLe+Aps and pAps (p<0.05) 
and correlated with disease activity and tissue factor 
expression. Galectin-9 correlated stronger than CXCL-10 
or tnF-rii with the iFn score (r=0.70, p<0.001) and 
was superior to CXCL-10 or tnF-rii in detecting the iFn 
signature (area under the curve (AUC) 0.86). importantly, 
in patients with sLe(±Aps), galectin-9 was also superior 
to anti-dsDnA antibody (AUC 0.70), or complement C3 
(AUC 0.70) and C4 (AUC 0.78) levels in detecting the 
iFn signature.
Conclusion Galectin-9 is a novel, easy to measure 
hence clinically applicable biomarker to detect the iFn 
signature in patients with systemic autoimmune diseases 
such as sLe and Aps.
Systemic lupus erythematosus (SLE) is a chronic 
relapsing autoimmune disease in which immune 
complexes of autoantibodies are deposited in tissues 
inducing tissue damage. Approximately 20% of 
patients with SLE have antiphospholipid syndrome 
(APS), defined as the persistent presence of anti-
phospholipid (aPL) antibodies in patients who 
experienced at least one thrombotic or predefined 
obstetric complication. APS also affects the patients 
without an underlying disease and is then termed 
primary APS (PAPS). The pathogenesis of SLE and 
APS is partly overlapping including shared genetic 
risk loci and perturbations in both the innate and 
adaptive immune system, although both conditions 
are only rarely studied together.1
Transcriptomic studies in SLE and APS have 
revealed a markedly increased expression of inter-
feron (IFN) inducible genes, known as the IFN 
signature which is present in ~75% of patients 
with SLE (±APS) and ~50% of patients with 
PAPS.2–5 In SLE, the IFN signature is associated 
with elevated autoantibody levels, disease activity, 
future flares and congenital heart block.3 4 6 7 In 
(P)APS, the IFN signature has only recently been 
reported and has been linked to endothelial 
progenitor cell dysfunction and increases in proin-
flammatory monocytes.2 5
 o
n
 23 M
arch 2019 by guest. Protected by copyright.
http://ard.bmj.com/
Ann R
heum
 D
is: first published as 10.1136/annrheum
dis-2018-213497 on 5 Septem
ber 2018. Downloaded from
 
1811van den Hoogen LL, et al. Ann Rheum Dis 2018;77:1810–1814. doi:10.1136/annrheumdis-2018-213497
Basic and translational research
Table 1 Clinical characteristics
HC (n=27) sLE (n=50) sLE+APs (n=40) PAPs (n=29)
Female (%) 93 96 95 97
Age 43 (34–50) 40 (28–48) 45 (37–53) 40 (33–50)
Disease manifestations 
  SLEDAI 4 (2–6) 4 (1–5) –
  Malar rash (%) 66 55 0
  Discoid rash (%) 22 18 0
  Photosensitivity (%) 42 53 0
  Oral ulcers (%) 36 35 0
  Arthritis (%) 70 65 0
  Serositis (%) 28 20 0
  Lupus nephritis (%) 60 45 0
  Neurologic disorder (%) 4 18 10
  Haematological disorder (%) 60 85 35
  Arterial thrombosis (%) 10 43 59
  Venous thrombosis (%) 4 60 38
  Obstetrical morbidity (%) 6 23 31
Current drug use 
  Hydroxychloroquine (%) 80 55 21
  Prednisone (%) 64 45 0
  Azathioprine (%) 34 33 0
  Oral anticoagulant (%) 2 75 62
  Aspirin (%) 22 28 48
Serology 
  C3 (g/L) 0.88 (0.69–1.03) 0.79 (0.68–0.92) –
  C4 (g/L) 0.16 (0.13–0.20) 0.15 (0.11–0.22) –
  a-dsDNA (IU/mL) 27 (6–114) 14 (5–58) –
  Lupus anticoagulant (%) 13 65 82
  IgG aCL (%) 15 78 86
  IgM aCL (%) 11 15 38
  IgG aβ2GPI (%) 7 26 35
  IgM aβ2GPI (%) 7 5 10
Medians with IQR or percentage of total.
aβ2GPI, anti-β2 glycoprotein I antibodies; aCL, anticardiolipin antibodies; a-dsDNA, anti-double stranded DNA antibodies; APS, antiphospholipid syndrome; HC, healthy control; 
PAPS, primary APS; SLE, systemic lupus erythematosus; SLEDAI, SLE Disease Activity Index.
The IFN signature is a promising therapeutic target. 
Anifrolumab, a monoclonal antibody against IFNAR, the 
receptor for type I IFN, showed clinical efficacy in a phase IIb 
clinical trial in SLE, particularly in those patients with an IFN 
signature.8 The detection of the IFN signature may therefore 
soon be used to guide treatment decisions in SLE and possibly 
other autoimmune diseases.
The IFN signature is measured by gene expression analysis. 
Therefore, easier to measure biomarkers for IFN signature 
detection are urgently needed. Measuring IFNα in periph-
eral blood seems the most straightforward method. However, 
IFNα is difficult to detect by standard techniques9 and the 12 
different IFNα proteins cannot be measured by a single assay. 
In addition, other type I IFNs (including IFNβ) as well as type 
II and III IFN (IFNγ and IFNλ) contribute to the IFN signa-
ture.10 Therefore, surrogate markers for the IFN signature 
were searched for Siglec-1 and CD64 expression on mono-
cytes, and serum levels of CXCL-10 correlate with the IFN 
signature in SLE and serve as alternatives to detect the IFN 
signature in SLE.6 11–13
Here, using an identification and replication approach we 
identified that galectin-9, CXCL-10 and tumour necrosis factor 
receptor type II (TNF-RII) correlate with the IFN signature 
and disease activity in patients with SLE and APS. Importantly, 
galectin-9 outperformed CXCL-10 or traditional markers of 
disease activity as an easy measurable biomarker to detect the 
IFN signature both in SLE and APS.
METHOds
Blood was drawn from patients with SLE, SLE+APS, PAPS and 
healthy controls (HC, table 1). Patients with PAPS did not meet 
the American College of Rheumatology criteria for SLE.14 The 
medical ethical committee of the UMC Utrecht approved the 
study and written informed consent was obtained.
Clinical and laboratory assessments
Serum analytes were measured as described in the online supple-
mentary methods15 in an initial identification cohort (n=43), 
followed by a replication step (n=148). For serum analytes, 
elevated levels were defined as 2 SDs above the mean of HC. 
Anti-dsDNA antibodies and complement levels were determined 
by EliA or nephelometry. Details on the assessment of the IFN 
signature, tissue factor (TF) expression and mRNA expression 
of galectin-9 in dendritic cells (DC) are provided in the online 
supplementary methods.
statistics
All tests were conducted two sided at an α level of 0.05. Statis-
tical tests used are provided in the figure legends.
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Figure 1 Galectin-9 is a biomarker for disease activity and tissue factor expression in SLE and APS. (A) Galectin-9, CXCL-10 and TNF-RII were 
measured by Luminex in sera of patients with SLE, SLE+APS and PAPS (Statistics: Kruskal-Wallis with post hoc Dunn’s). Dotted line represents the 
mean of HC+2 SD. (B) Correlation of galectin-9, CXCL-10 and TNF-RII with disease activity in patients with SLE and SLE+APS. (C) Correlation of 
galectin-9, CXCL-10 and TNF-RII tissue factor (TF) expression in monocytes in patients with SLE+APS and PAPS as assessed by qPCR (-dCq, delta 
quantification cycle). Statistics: (A) Kruskal-Wallis followed by post hoc Dunn’s. (B, C) Spearman correlation coefficients. APS, antiphospholipid 
syndrome; HC, healthy control; PAPS, primary APS; SLE, systemic lupus erythematosus; SLEDAI, SLE Disease Activity Index; TNF-RII, tumour necrosis 
factor receptor type II.
rEsuLTs
Galectin-9, CXCL-10 and TNF-rII are biomarkers of disease 
activity in sLE and APs
In an initial screening of 22 serum analytes, galectin-9 (r=0.81, 
p<0.001), CXCL-10 (r=0.72, p<0.001) and TNF-RII (r=0.42, 
p=0.007) correlated significantly with the IFN score in patients 
with SLE, SLE+APS and PAPS (n=43, online supplementary 
table and figure 1). We next assessed these analytes in a larger 
replication step (n=148). Galectin-9, CXCL-10 and TNF-RII 
levels were significantly elevated in patients with SLE, SLE+APS 
and PAPS as compared with HC (figure 1A). Elevated levels of 
galectin-9 were present in 74%, 68% and 41% of patients with 
SLE, SLE+APS and PAPS, respectively, compared with 46%, 55% 
and 45% for CXCL-10% and 46%, 50% and 41% for TNF-RII. 
All three analytes correlated with anti-dsDNA antibodies and 
complement levels in patients with SLE (online supplementary 
figure 2). Furthermore, galectin-9 and TNF-RII, not CXCL-
10, correlated with disease activity as assessed by SLE Disease 
Activity Index (figure 1B). In patients with APS, the increased 
expression of TF by monocytes is induced by aPL antibodies and 
reflects a prothrombotic phenotype,1 and we found significant 
correlations between galectin-9, CXCL-10 and TNF-RII and the 
expression of TF by monocytes in patients with APS (figure 1C).
Galectin-9 is a biomarker to detect the IFN signature in sLE 
and APs
A superior correlation of galectin-9 with the IFN score 
(r=0.70, p<0.001) as compared with CXCL-10 (r=0.52, 
p<0.001) and TNF-RII (r=0.46, p<0.001) was found 
(figure 2A). Receiver operating characteristic curve analysis 
revealed the highest area under the curve (AUC, 0.86) for 
galectin-9, followed by CXCL-10 (0.78) and TNF-RII (0.75) 
for the detection of the IFN signature (figure 2B) among 
patients with SLE or APS. When focusing only on patients 
with SLE(±APS), galectin-9 (AUC 0.84) remained a supe-
rior biomarker to detect the IFN signature compared with 
CXCL-10 (AUC 0.75) or TNF-RII (AUC 0.70) or traditional 
markers of SLE disease activity such as anti-dsDNA anti-
bodies (AUC 0.70) or complement levels (C3: AUC 0.70, C4: 
AUC 0.78) (figure 2C). Elevated levels of galectin-9 had a 
sensitivity of 84% and a positive predictive value of 91% of 
detecting the IFN signature among patients with SLE(±APS) 
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Figure 2 In SLE and APS, galectin-9 outperforms CXCL-10 and traditional markers for disease activity as biomarker for the IFN signature and is 
upregulated in dendritic cells. (A) Correlation of galectin-9, CXCL-10 and TNF-RII with the IFN score. (B) ROC curve analysis of galectin-9, CXCL-10 
and TNF-RII in the detection of the IFN signature in patients with SLE, SLE+APS and PAPS. (C) ROC curve analysis of galactin-9, CXCL-10 and TNF-RII 
as compared with traditional markers of SLE disease activity in detecting the IFN signature among patients with SLE±APS. (D) Test characteristics of 
elevated galectin-9, CXCL-10, TNF-RII, anti-dsDNA antibodies or reduced complement levels to detect the IFN signature in patients with SLE(±APS). 
(E) Expression of galectin-9 coding gene LGALS9 in myeloid and plasmacytoid DCs as assessed by RNAseq in patients with SLE and APS stratified by 
IFN status. (F) Expression of LGALS9 assessed by qPCR after in vitro stimulation of DCs with IFNα for 3 hours (n=3/group). Statistics: (A) Spearman 
correlation coefficients. (E) ANOVA with post hoc Tukey’s or Student’s t-test. (F) Student’s t-test. ANOVA, analysis of variance; APS, antiphospholipid 
syndrome; AUC, area under the curve; HC, healthy control; IFN, interferon; mDC, myeloid dendritic cells; NPV, negative predictive value; PAPS, primary 
APS; pDC, plasmacytoid dendritic cells; PPV, positive predictive value; ROC, receiver operating characteristic; SLE, systemic lupus erythematosus; TNF-
RII, tumour necrosis factor receptor type II.
(figure 2D). In multivariate linear regression analysis 
galectin-9 was an independent predictor for the IFN score, 
and remained significant after correction for anti-dsDNA 
antibodies, complement levels and disease activity.
Increased expression of galectin-9 in dCs of IFN-positive 
patients with sLE and APs
Galectin-9 is a β-galactoside-binding lectin, encoded by the gene 
LGALS9 which is highly expressed in DCs.16 Therefore, we 
explored the expression of LGALS9 in myeloid and plasmacy-
toid DCs (mDC/pDC) in SLE and APS. LGALS9 expression was 
markedly higher in circulating DCs of patients with SLE and APS 
with an IFN signature and IFNα increased LGALS9 expression 
in vitro in mDCs and pDCs (figure 2E,F).
dIsCussION
Here we report that galectin-9, CXCL-10 and TNF-RII are 
elevated and associated with disease activity in SLE and APS. 
Notably, we identified galectin-9 as a robust and easy to measure 
biomarker to detect the IFN signature, outperforming tradi-
tional biomarkers for the IFN signature such as CXCL-10.
Measuring the IFN signature in patients with SLE might in 
the future be used in clinical decision-making.8 The necessity to 
quantify gene expression and the lack of a uniformly accepted 
gene set or scoring system hamper its implementation in clin-
ical practice. Furthermore, serum biomarkers are more easily 
standardised and are less laborious as compared with previously 
proposed biomarkers for the IFN signature that are assessed by 
flow cytometry.12 13 In this respect, galectin-9 is a promising 
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stable biomarker, which is superior to CXCL-10 in the detection 
of the IFN signature, both in SLE and APS, and can furthermore 
be reliably detected in serum samples stored for long periods.17
Besides serving as a biomarker, galectin-9 may play a role in 
the pathogenesis of SLE and APS. Galectin-9 induces the matura-
tion of DCs by increasing the expression of HLA-DR and costim-
ulatory molecules and galectin-9 produced by DCs activates T 
cells.16 Galectin-9 expression was markedly increased in DCs of 
IFN-positive patients with SLE and APS and may therefore drive 
the unabated activation of DCs seen in these patients. Further-
more, in the pristane-induced SLE mouse model, knockout of 
LGALS9 results in reduced nephritis and arthritis,18 supporting a 
pathogenic role for galectin-9 in the pathogenesis of SLE. Besides 
IFNα, galectin-9 may also be induced by other proinflammatory 
mediators implicated in the pathophysiology of autoimmune 
diseases,19 hence the applicability of galectin-9 as a biomarker 
for immunopathology in other diseases warrants further study.
The treatment of SLE and APS has remained largely unchanged 
for decades. The revolution in the treatment of other rheumatic 
conditions, most notably rheumatoid arthritis, in the last decades 
has not been paralleled in SLE and APS in which few clinical trials 
have met their primary outcome. A major reason for the failure 
of these trials is the molecular heterogeneity of these diseases. 
Consequently, for SLE and APS there is an urgent need for a 
more personalised treatment approach, guided by the molecular 
phenotype rather than clinical diagnosis. Treatment of patients 
on the basis of the presence of an IFN signature could represent 
such a molecular phenotype, supported by the results from the 
anifrolumab trial.8 Galectin-9 may serve as a robust and easy to 
measure biomarker to detect the IFN signature in patients with 
SLE and APS, as well as other (systemic) autoimmune diseases.
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